Antiplatelet therapy in peripheral artery disease

Handbook of Experimental Pharmacology

Volumn 210, Issue , 2012, Pages 547-563

  Violi, Francesco ^a   Basili, Stefania ^a   Berger, Jeffrey S ^b   Hiatt, William R ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Ankle Brachial Index; Antiplatelet Agents; Aspirin; Peripheral Artery Disease; Thienopyridines

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE RECEPTOR; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; PICOTAMIDE; PLACEBO; PRASUGREL; RECEPTOR; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ANKLE BRACHIAL INDEX; ARACHIDONIC ACID METABOLISM; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXERCISE; HEART INFARCTION; HUMAN; INHIBITION KINETICS; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; META ANALYSIS (TOPIC); MONOTHERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; METABOLISM; REVIEW;

ANKLE BRACHIAL INDEX; ARACHIDONIC ACID; ASPIRIN; HUMANS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84867169035     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-29423-5_22     Document Type: Article

References (53)

1. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD et al (2008) Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a metaanalysis. JAMA 300:197-208
2. U.S. Food and Drug Administration (1998) Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Fed Regist 63: 56802-56819
3. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
4. Aronow WS (2010) Office management of peripheral arterial disease. Am J Med 123:790-792
5. Balsano F, Violi F (1993) Effect of picotamide on the clinical progression of peripheral vascular disease.Adouble-blind placebo-controlled study. The ADEP Group. Circulation 87:1563-1569
6. Balsano F, Coccheri S, Libretti A et al (1989) Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med 14:84-91
7. Basili S, Raparelli V, Vestri AR et al (2010) Comparison of efficacy of antiplatelet treatments for patients with claudication: a meta-analysis. Thromb Haemost 103:766-773
8. Beckman JA, Jaff MR, Creager MA (2006) The United States Preventive Services Task Force recommendation statement on screening for peripheral arterial disease: more harm than benefit? Circulation 114:861-866
9. Belch JJ, Topol EJ, Agnelli G et al (2003) Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163:884-892
10. Belch J, MacCuish A, Campbell I et al (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840
11. Berger JS, Krantz MJ, Kittelson JM et al (2009) Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301:1909-1919
12. Berger JS, Eraso LH, Xie D et al (2010) Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis 213:586-591
13. Berrettini M, De Cunto M, Parise P et al (1990) "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and-receptor antagonist, on human platelets. Eur J Clin Pharmacol 39:495-500
14. Bhatt DL, Steg PG, Ohman EM et al (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295:180-189
15. Bhatt DL, Flather MD, Hacke W et al (2007) Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49:1982-1988
16. Blann AD, Tan KT, Tayebjee MH et al (2005) Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 93:578-583
17. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
18. Cattaneo M, Tenconi PM, Lecchi A et al (1991) In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. Thromb Res 62:717-724
19. Creager MA, White CJ, Hiatt WR et al (2008) Atherosclerotic Peripheral Vascular Disease Symposium II: executive summary. Circulation 118:2811-2825
20. Criqui MH, Fronek A, Barrett-Connor E et al (1985) The prevalence of peripheral arterial disease in a defined population. Circulation 71:510-515
21. Criqui MH, Alberts MJ, Fowkes FG et al (2008) Atherosclerotic Peripheral Vascular Disease Symposium II: screening for atherosclerotic vascular diseases: should nationwide programs be instituted? Circulation 118:2830-2836
22. Critical Leg Ischaemia Prevention Study (CLIPS) Group, Catalano M, Born G et al (2007) Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 261:276-284
23. Dav G, Gresele P, Violi F et al (1997) Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 96:69-75
24. Doobay AV, Anand SS (2005) Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol 25: 1463-1469
25. FitzGerald GA (1991) Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 68:11B-15B
26. Fowkes FG, Price JF, Stewart MCWet al (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index. JAMA 303:841-848
27. Goldhaber SZ, Manson JE, Stampfer MJ et al (1992) Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 340:143-145
28. Gresele P, Deckmyn H, Arnout J et al (1989) Characterization of N, N0-bis(3-picolyl)-4-methoxyisophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thromb Haemost 61:479-484
29. Haugen S, Casserly IP, Regensteiner JG et al (2007) Risk assessment in the patient with established peripheral arterial disease. Vasc Med 12:343-350
30. Hiatt WR, Goldstone J, Smith SC Jr et al (2008) Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation 118:2826-2829
31. Hirsch AT, Criqui MH, Treat-Jacobson D et al (2001) Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286:1317-1324
32. Hirsch AT, Haskal ZJ, Hertzer NR et al (2006a) ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113:e463-e654
33. Hirsch AT, Haskal ZJ, Hertzer NR et al (2006b) ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 47:1239-1312
34. Janzon L, Bergqvist D, Boberg J et al (1990) Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 227:301-308
35. Kannel WB, McGee DL (1985) Update on some epidemiologic features of intermittent claudiation: the Framingham Study. J Am Geriatr Soc 33:13-18
36. McDermott MM, Greenland P, Liu K et al (2002) The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 136:873-883
37. McDermott MM, Liu K, Criqui MH et al (2005) Ankle brachial index and subclinical cardiac and carotid disease: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 162:33-41
38. Meijer WT, Hoes AW, Rutgers D et al (1998) Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 18:185-192
39. Milani M, Longoni A, Maderna M (1996) Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br J Clin Pharmacol 42:782-785
40. Modesti PA, Colella A, Abbate R et al (1989) Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide. Eur J Pharmacol 169:85-93
41. Modesti PA, Cecioni I, Colella A et al (1994) Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist. Br J Pharmacol 112:81-86
42. Neri Serneri GG, Coccheri S, Marubini E et al (2004) Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 25:1845-1852
43. Norgren L, Hiatt WR, Dormandy JA et al (2007a) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45:S5-S67
44. Norgren L, Hiatt WR, Dormandy JA et al (2007b) Inter-society consensus for the management of peripheral arterial disease. Int Angiol 26:81-157
45. O'Hare AM, Katz R, Shlipak MG et al (2006) Mortality and cardiovascular risk across the anklearm index spectrum: results from the Cardiovascular Health Study. Circulation 113:388-393
46. Pande RL, Perlstein TS, Beckman JA et al (2011) Secondary Prevention and Mortality in Peripheral Artery Disease. National Health and Nutrition Examination Study, 1999 to 2004. Circulation 124:17-23
47. Resnick HE, Lindsay RS, McDermottMMet al (2004) Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 109:733-739
48. Rosamond W, Flegal K, Furie K et al (2008) Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25-e146
49. Sobel M, Verhaeghe R, American College of Chest Physicians et al (2008) Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:815-843
50. Steg PG, Bhatt DL, Wilson PW et al (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297:1197-1206
51. Stehouwer CD, Clement D, Davidson C et al (2009) EFIM Vascular Medicine Working Group. Peripheral arterial disease: a growing problem for the internist. Eur J Intern Med 20:132-138
52. Violi F, Ghiselli A, Iuliano L et al (1988) Inhibition by picotamide of thromboxane production in vitro and ex vivo. Eur J Clin Pharmacol 33:599-602
53. White C (2007) Clinical practice. Intermittent claudication. N Engl J Med 356:1241-1250